The 2024 American Heart Association Scientific Sessions were held in Chicago, Illinois, over November 16 to 18, 2024. Highlights from the conference included the latest data from drug candidates offering new therapeutic interventions related to the management of various cardiovascular health including lipid disorders, chronic heart failure, cardiomyopathies, and pulmonary hypertension. Preclinical and clinical research covering investigational assets with novel mechanisms of action was also presented. Conference highlights include:

• • PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
  • ENDEAVOR - Myeloperoxidase Inhibition with Mitiperstat in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Primary Results from the ENDEAVOR Randomized Clinical Trial
  • ALPACAR - Phase 2 Trial of Zerlasiran: Multiple doses of a Short-Interfering RNA Targeting Lipoprotein(a) over 60 weeks

This post-meeting report features commentary from our analysts on specific presentations. It also includes a compilation of data events added in conjunction with the meeting.